Will you lose more weight on 7.5mg of Mounjaro?

Weight loss with tirzepatide tends to increase at higher doses: SURMOUNT-1 trial data show progressively greater average reductions from 5mg through to 15mg. Source: SURMOUNT-1, NEJM
7.5mg is a mid-range therapeutic dose, it follows 2.5mg and 5mg in the licensed schedule, moving you into a range where meaningful weight loss is well-documented in trials.
The strength of your response at 7.5mg depends on individual factors: your starting weight, how your body has tolerated earlier doses, your diet and activity, and your wider health picture.
A dose increase is only appropriate when your prescriber confirms you have tolerated the previous pen and that the clinical evidence supports moving up, this review is built into the nume process at every step.

Moving to 7.5mg of Mounjaro does, for many people, bring a noticeable step up in weight loss — but the picture is more nuanced than a simple yes. Clinical trial data show that weight reduction with tirzepatide generally increases as the dose rises, with the largest average losses recorded at the highest doses. That pattern holds for most people, though not everyone responds the same way, and your prescriber is the one who decides whether a dose increase is appropriate for you. As a prescription-only medicine, every step up requires a clinical review — not just a request.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How dose increases work in practice, and what the evidence says about 7.5mg

Step 1: understanding where 7.5mg sits in the titration sequence

Mounjaro's licensed UK schedule runs from 2.5mg (a dose designed to let your system adjust) up through 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, with each step typically taken in four-week intervals under prescriber guidance. The early pens are largely about tolerability. By the time you reach 7.5mg, your body has had at least eight weeks on tirzepatide, and the medicine is working at a dose where clinical trials recorded meaningful weight reduction.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, is the clearest reference point here. Over 72 weeks, participants on 5mg lost an average of around 16% of their body weight; those on 10mg lost around 21%; and those on 15mg lost around 22.5%. The 7.5mg dose sits between the 5mg and 10mg figures in that curve. Individual results varied considerably, but the overall direction of the data is clear: more tirzepatide, for most people, means more weight lost, up to a point where the curve begins to flatten at higher doses.

What this means practically is that moving from 5mg to 7.5mg is a genuine therapeutic step, not just a bureaucratic one. Many people notice the difference within a few weeks of the new pen. If you want to understand how higher doses compare across the full schedule, that context is worth reading before your next review.

Step 2: what your prescriber looks at before approving the increase

A dose increase is not automatic. Before moving from 5mg to 7.5mg, a clinician needs to be satisfied that you tolerated the previous dose without significant problems, GI side effects like nausea, vomiting, or diarrhoea that haven't settled, for instance, are a reason to pause rather than push. Your current weight loss is also part of the picture: if you are still losing steadily at 5mg without distress, there may be no clinical need to step up yet.

At nume, every repeat and every dose change is reviewed by a GPhC-registered Independent Prescriber before anything is dispensed. That review includes evidence of your current dose and weight, not just a checkbox. This matters because the people who do best on higher doses are those who have been properly titrated, not rushed. If you have questions about the review process, the frequently asked questions page covers how it works in detail.

Side effects are common in the first week or two after a dose increase and usually settle. The NHS tirzepatide information page lists the most commonly reported ones: nausea, loose stools, indigestion, and fatigue lead the list. Severe or persistent stomach pain that radiates to the back is a reason to seek medical help promptly rather than wait.

Step 3: realistic expectations at 7.5mg and beyond

People sometimes expect a sharp jump in weight loss the week they move to a new pen. In reality, the body takes a little time to respond to each increase, and the scale may not reflect the change immediately. Staying consistent (meals that prioritise protein and vegetables, keeping well-hydrated, not skipping the movement you've built in) matters as much at 7.5mg as it did at the start.

It's also worth knowing that not everyone needs to reach 15mg. Some people lose weight steadily at 7.5mg or 10mg and have no reason to go higher. The aim is the lowest dose at which you're making good progress without troublesome side effects, not the highest dose you can tolerate. Your prescriber will keep that balance in view at each review.

One practical note: if your dose increase lands at an awkward time (around a holiday, or just after a pay cycle when ordering feels inconvenient) ordering by noon on a weekday means dispatch the same day and delivery the following working day, so planning a week ahead keeps you covered. If you'd like a broader overview of what to expect on the 5mg pen before your move to 7.5mg, that page is a useful reference, and for a closer look at whether 5mg is likely to produce results for you, that question is answered in detail there too. For people who have already started the 5mg pen and want to know whether increasing within that dose range makes a meaningful difference, that is also covered. For people earlier in the process still weighing up their options, what happens at the starter dose is also documented. And if cost is a consideration as treatment progresses, the treatment pricing page sets out what's included in one transparent figure, no extras for the clinical review or delivery.

The short answer to the original question: yes, for most people, 7.5mg produces more weight loss than 5mg, but the increase is earned through consistent treatment, proper titration, and a prescriber who confirms the step is right for you. Speak to our prescribers if you're ready to discuss where you are in the dose schedule and what comes next.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions